In this new tumor classification, a mutation inthe isocitrate dehydrogenase (IDH) gene is an important molecular marker in gliomadiagnosis, with significant implications for tumor behavior and patientprognosis(9,10). This evidence concerns the gene IDH1 and neoplasm.